The Medicines Company's antiplatelet drug cangrelor fails Phase III
This article was originally published in Scrip
Executive Summary
The Medicines Company has discontinued its Phase III CHAMPION development programme for its novel intravenous antiplatelet therapy cangrelor after interim analyses showed that both studies in the programme were unlikely to succeed.